FDA Issues Guidance on Summaries for CTD-based Submissions

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration finalized a Guidance for Industry this week that aims to clarify the submission of new drug applications (NDAs) and biologics license applicants (BLAs) using the common technical document (CTD) format, including the electronic CTD (eCTD).

The US Food and Drug Administration finalized a Guidance for Industry this week that aims to clarify the submission of new drug applications (NDAs) and biologics license applicants (BLAs) using the common technical document (CTD) format, including the electronic CTD (eCTD). Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document provides information about where in the CTD the integrated summary of effectiveness (ISE) and integrated summary of safety (ISS) should be placed. This information is required for NDAs and recommended for BLAs.

The ISE and ISS issues have created some confusion in the industry, particularly the word “summary” in both terms. According to the guidance, “A common problem with the CTD-formatted applications is that applicants incorrectly assume that the clinical summary sections satisfy the regulatory requirement for the ISE and ISS. This assumption can result in a determination by the FDA that an application is incomplete and may result in a refusal-to-file action for the application.” The document clarifies, however, “the ISE and ISS are not summaries but rather detailed integrated analyses of all relevant data from the clinical study reports that belong in Module 5” and not the clinical summary section.

The guidance also aims to provide specifics regarding ISS and ISE reports that are not covered in the International Conference on Harmonization (ICH) 2001 guidance M4 Common Technical Document for the Registration of Pharmaceuticals for Human Use,  specifically in M4E: The CTD-Efficacy.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes